Long-Acting Injectable PrEP for HIV Risk
October 03, 2021
Long-acting pre-exposure prophylaxis (PrEP) is not only a long sought-after measure of HIV control in the infectious disease community—it’s a now tangible opportunity that would alter both diagnostics and care. In an interview with Contagion during IDWeek 2021, Raphael J. Landovitz, MD, MSc, of the UCLA Center for Clinical AIDS Research & Education, reviewed his own presentation on the current
18th Annual HIV CME Symposium Tough Decisions Made Easier
September 09, 2021
The UCLA Center for Clinical AIDS Research & Education (CARE), UCLA Pacific AIDS Education Training Center (PAETC), UCLA AIDS Institute, and Center for HIV Identification, Prevention and Treatment Services (CHIPTS) proudly present the 18th Annual HIV CME Symposium "Tough Decisions Made Easier: Clinical Management of Treatment - Experienced Patients." This one-day virtual symposium is designed to
Bimonthly, Injected PrEP Beats Daily Pill in Warding Off HIV: Study
August 12, 2021
When the antiretroviral regimen known as pre-exposure prophylaxis, or PrEP, was launched nearly a decade ago, patients were suddenly able to achieve near-complete protection against contracting HIV by taking just one pill a day. Full news release on www.usnews.com
A5391: A study to see if a new HIV treatment regimen can reduce weight or slow weight gain
The primary purpose of this study is to see if people with HIV who had a significant weight gain after starting INSTI (integrase strand transfer inhibitor)+TAF/FTC (tenofovir alafenamide/emtricitabine) (TAF/3TC [lamivudine]) regimen could either slow their rate of weight gain or lose weight within about 1 year if they switch to a regimen containing doravirine (DOR; a newer, non-nucleoside reverse transcriptase inhibitor medication). Interested in Volunteering? Have you experienced weight gain while on antiretroviral therapy? The Do It Study is looking for people living with HIV who have experienced weight gain from taking a treatment regimen that contains an integrase inhibitor like Tivicay, Issentress, or (one of the drugs contained in Biktarvy) plus tenofovir alafenamide (TAF) Basic Eligibility Requirement: Age 18+ Living with HIV Currently on an ART regimen containing an integrase inhibitor and TAF without interruption over 48 weeks Experienced >10% weight gain in 1-3 years after starting these medications Have a body mass index (BMI) > 27.5 Principal Investigator: Raphael J. Landovitz, MD, MSc For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI). Interested in Volunteering? We are looking for HIV+ people who are taking antiretroviral treatment (ART) and whose viral load is undetectable. The goal is to find out if IL-15 is safe alone or when used in combination with another treatment called broadly neutralizing antibodies (bNAbs). Participants will receive 8 doses of IL-15 given every 3 weeks. Half of the participants will be randomly assigned to also receive the bNAbs with it. After completing these treatments, participants will temporarily stop taking their HIV medicine (ART) and will be evaluated to see how well this treatment controls their viral load. Basic Eligibility Criteria: Age: 18-65 years old Status: HIV Positive Continuous HIV treatment: at least 96 weeks Viral load: Undetectable at least 96 weeks Coinfection: No active hepatitis B or C infection CD4 count: More than 500 Principal Investigator: Kara Chew, MD, MS For more information, please contact the UCLA CARE Center: [email protected] 310-843-2015 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
Antibodies that develop naturally against HIV recognize and attach to one part of the virus so that the body’s immune system can try to attack it. Antibodies are usually made by a person’s own immune system, but they can also be manufactured as a drug. SAR441236 has been manufactured to attach to three parts of the HIV virus at the same time, and to neutralize (or block) the ability of the virus to infect more cells. A5377 is the first study of SAR441236 in humans. This study will enroll two groups of people with HIV: Arm A—people who are on an anti-HIV regimen with an undetectable HIV viral load will receive either SAR441236 or placebo in four increasing dosing groups; and Arm B—people who have never received anti-HIV medications will receive SAR441236 in four increasing dosing groups. Interested in Volunteering? This UCLA research study is for people living with HIV who are not currently on ART. You may qualify if you: Are 18 years of age or older Are HIV+ Have a CD4+ cell count of at least 350 Are not currently taking antiretrovirals (ART) Are willing to start ART after 28 days on the study Have no Hepatitis B or C infection Principal Investigator: Raphael Landovitz, MD, MSc For more information, contact the UCLA CARE Center at: [email protected] 310-557-9062 If you would prefer to have a community outreach coordinator or research coordinator reach out to you, please leave your contact information below and someone will reach out to you shortly.
